European Haemophilia Consortium (EHC)
Search

Archiv

11.10.2010

Washington Week: Flu Guidelines Released

WASHINGTON -- A sure sign that summer is over: the CDC issued the nation's annual flu guidelines this week, recommending that every American older than six months -- including pregnant women -- get vaccinated. In addition,...[подробнее]

11.10.2010

U.K. bars CFS patients from donating blood

Starting Nov. 1, patients with chronic fatigue syndrome will no longer be allowed to donate blood in the U.K. as "a precaution to protect the donor's safety by ensuring their condition is not made worse by donating...[подробнее]

07.10.2010

Hoffman-La Roche buys rights to danoprevir from InterMune

Hoffman-La Roche paid InterMune $175 million for rights to develop and market danoprevir, a drug for hepatitis C. The companies, which had been working on the drug since October 2006, said they are exploring options to continue...[подробнее]

07.10.2010

HGS and Novartis stop developing hepatitis C drug Zalbin

Human Genome Sciences and partner Novartis are discontinuing work on Zalbin, a treatment for hepatitis C, after the companies received a complete-response letter from the FDA. The agency previously cited concern about the safety...[подробнее]

02.10.2010

Expert raises contamination issue in unresolved XMRV-CFS findings

British retrovirologist Robin Weiss said that with the question on the link between the XMRV retrovirus and chronic fatigue syndrome still unresolved, reassessing whether contamination is the problem might help. Weiss said there...[подробнее]

02.10.2010

Neurological Risks of HIV Remain High (CME/CE)

People with HIV remain at a surprisingly high risk of neurological disorders -- ranging from neuropathy to dementia -- despite the success of combination antiretroviral therapy, researchers reported. In a population-based study...[подробнее]

02.10.2010

FDA Sets New Rules for Reporting Adverse Trial Events

WASHINGTON -- The FDA has finalized new procedures aimed at speeding up reporting and analysis of potential safety problems encountered in clinical trials while cutting down on adverse-event filings the agency considers useless....[подробнее]

Displaying 15 to 21 of 22